SEC Comment Letter for SUTRO BIOPHARMA, INC. (STRO) (CIK 0001382101) (STRO) — Oct 8, 2019
SUTRO BIOPHARMA, INC. (STRO) (CIK 0001382101)
Date: Oct. 8, 2019 · CIK: 0001382101 · Accession: 0000000000-19-014405
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-234101
Letter
October 8, 2019 William J. Newell Chief Executive Officer Sutro Biopharma, Inc. 310 Utah Avenue, Suite 150 South San Francisco, CA 94080 Re:Sutro Biopharma, Inc. Registration Statement on Form S-3 Filed October 4, 2019 File No. 333-234101 Dear Mr. Newell: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Ryan Mitteness, Esq.
Show Raw Text
October 8, 2019
William J. Newell
Chief Executive Officer
Sutro Biopharma, Inc.
310 Utah Avenue, Suite 150
South San Francisco, CA 94080
Re:Sutro Biopharma, Inc.
Registration Statement on Form S-3
Filed October 4, 2019
File No. 333-234101
Dear Mr. Newell:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jeffrey Gabor at 202-551-2544 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Ryan Mitteness, Esq.